Pathstone Family Office, LLC Axsome Therapeutics, Inc. Transaction History

Pathstone Family Office, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Oct 23, 2023	BUY	$39.94 - $79.72 $103,844 - $207,272	2,600 New	2,600 $200,000
Q4 2022 Feb 13, 2023	BUY	$39.94 - $79.72 $103,844 - $207,272	2,600 New	2,600 $200,000
Q1 2021 May 14, 2021	SELL	$55.91 - $81.44 $91,133 - $132,747	-1,630 Closed	0 $0
Q3 2020 Nov 12, 2020	BUY	$68.34 - $85.84 $82,008 - $103,008	1,200 Added 279.07%	1,630 $116,000
Q2 2020 Aug 14, 2020	SELL	$49.87 - $98.69 $11,220 - $22,205	-225 Closed	0 $0
Q1 2020 Jun 11, 2020	BUY	$41.2 - $101.31 $9,270 - $22,794	225 New	225 $13,000

326

37.7M

912K

855K

Ticker AXSM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,878,000
Market Cap $3.99B
Description
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinic...

Get notified when there are updates to the investment portfolio of Pathstone Family Office, LLC, based on Form 13F filings with the SEC.

Stay updated on Pathstone Family Office, LLC with notifications on news.